Tin tức & Cập nhật
Xem bài viết Nội tiết
Xem

Growth hormone reduces liver fat, fibro-inflammation in obese/overweight adults with NAFLD
In adults with overweight/obesity and nonalcoholic fatty liver disease (NAFLD), daily administration of growth hormone (GH) reduced hepatic steatosis and improved markers of hepatic inflammation and fibrosis, a study has shown.

Empagliflozin shows promise for chronic SIAD-induced hyponatremia
The sodium-glucose cotransporter 2 inhibitor empagliflozin showed potential as a treatment alternative for hyponatremia due to chronic syndrome of inadequate antidiuresis (SIAD), according to a trial presented at ENDO 2022.

Obese/overweight patients incur 10 percent long-term weight loss with lifestyle management, medication
Individuals who are overweight or obese can achieve an approximately 10 percent weight loss over 3–5 years with the use of anti-obesity medications in addition to lifestyle management, according to a retrospective study presented at ENDO 2022.

Lower diabetes risk test cutoff ups lab cost, identifies more persons with prediabetes
Use of the American Diabetes Association (ADA) Diabetes Risk Test (DRT) cutoff score of 4 as part of an employee wellness screening program to identify individuals at risk for developing the disease adds up to laboratory costs, reports a study.




